69124 Federal Register / Vol. 79, No. 224 / Thursday, November 20, 2014 / Notices 

individuals based on their responses to 

these questions. 

(Comment 7) ‘‘Lilly suggests that the 

survey design be improved to better 

align with the research objectives, to 

avoid bias and to mitigate extreme 

respondent fatigue. Lilly recommends 

that FDA modify the data collection 

instrument to address the points noted 

above and seek additional public 

comment on the revised design.’’ 

(Response) Given our responses and 

points of clarification above, we believe 

that the current design is rigorous and 

meets FDA’s research objectives. The 

design allows us to test and validate 

measurement items for consumers’ risk 

and benefit perceptions. By 

randomizing respondents to the various 

ads with different benefit and risk 

information, we have controlled for 

underlying differences in respondent 

demographics and thereby have reduced 

the potential for selection bias (Ref. 4) 

and enhanced study validity. As we 

have described above, we also have 

designed the study to minimize 

respondent fatigue by testing only the 

most promising candidate items and by 

ensuring a survey length of no more 

than 30 minutes. 

TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN1

Activity Number of 

respondents 

Number of 

responses per 

respondent 

Total annual 

responses Hours per response 2 Total hours 

Pretest screener ................................ 2,000 1 2,000 0.03 (2 minutes) ............................... 60 

Main study screener ......................... 20,000 1 20,000 0.03 (2 minutes) ............................... 600 

Pretest ............................................... 2 1,100 1 1,100 .5 (30 minutes) ................................. 550 

Main Study ........................................ 10,200 1 10,200 .5 (30 minutes) ................................. 5,100 

Total ........................................... ........................ ........................ ........................ ........................................................... 6,310 

1There are no capital costs or operating and maintenance costs associated with this collection of information. 

2With online surveys, several participants may be completing the survey at the time that the total target sample is reached. Those participants 

are allowed to complete the survey, which can result in the number of completes going slightly over the target number. Thus, if our target is 

1,000, we have rounded up by an additional 100 to allow for some overage. 

III. References 

The following references have been 

placed on display in the Division of 

Dockets Management (see ADDRESSES) 

and may be seen by interested persons 

between 9 a.m. and 4 p.m., Monday 

through Friday, and are available 

electronically at http://

www.regulations.gov. 

1. Lipkus, I. M., ‘‘Numeric, Verbal, and 

Visual Formats of Conveying Health 

Risks: Suggested Best Practices and 

Future Recommendations,’’ Medical 

Decision Making, 27(5), 696–713 (2007). 

2. Aikin, K. J., J. L. Swasy, and A.C. Braman, 

‘‘Patient and Physician Attitudes and 

Behaviors Associated with DTC 

Promotion of Prescription Drugs— 

Summary of FDA Survey Research 

Results,’’ FDA, Center for Drug 

Evaluation and Research, 19 (2004). 

3. Horne, R., J. Weinman, and M. Hankins, 

‘‘The Beliefs About Medicines 

Questionnaire: The Development and 

Evaluation of a New Method for 

Assessing the Cognitive Representation 

of Medication,’’ Psychology and Health, 

14, 1–24 (1999). 

4. Kunz, R., G. E. Vist, and A. D. Ochman, 

‘‘Randomization to Protect Against 

Selection Bias in Healthcare Trials,’’ The 

Cochrane Library, Issue 2 (2008). 

Dated: November 14, 2014. 

Leslie Kux, 

Associate Commissioner for Policy. 

[FR Doc. 2014–27431 Filed 11–19–14; 8:45 am] 

BILLING CODE 4164–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Health Resources and Services 

Administration 

National Vaccine Injury Compensation 

Program: Revised Amount of the 

Average Cost of a Health Insurance 

Policy 

The Health Resources and Services 

Administration (HRSA) is publishing an 

updated monetary amount of the 

average cost of a health insurance policy 

as it relates to the National Vaccine 

Injury Compensation Program (VICP). 

Section 100.2 of the VICP’s 

implementing regulation (42 CFR Part 

100) states that the revised amounts of 

an average cost of a health insurance 

policy, as determined by the Secretary, 

are to be published periodically in a 

notice in the Federal Register and filed 

with the United States Court of Federal 

Claims (the Court). This figure is 

calculated using the most recent 

Medical Expenditure Panel Survey— 

Insurance Component (MEPS–IC) data 

available as the baseline for the average 

monthly cost of a health insurance 

policy. This baseline is adjusted by the 

annual percentage increase/decrease 

obtained from the most recent annual 

Kaiser Family Foundation and Health 

Research and Educational Trust (KFF/

HRET) Employer Health Benefits survey 

or other authoritative source that may be 

more accurate or appropriate. 

In 2014, MEPS–IC, available at 

www.meps.ahrq.gov, published the 

annual 2013 average total single 

premium per enrolled employee at 

private-sector establishments that 

provide health insurance. The figure 

published was $5,571. This figure is 

divided by 12-months to determine the 

cost per month of $464.25. The $464.25 

shall be increased or decreased by the 

percentage change reported by the most 

recent KFF/HRET, available at 

www.kff.org. The percentage increase 

from 2013 to 2014 was published at 2 

percent. By adding this percentage 

increase, the calculated average monthly 

cost of a health insurance policy is 

$473.54 for 2014. 

Therefore, the Secretary announces 

that the revised average cost of a health 

insurance policy under the VICP is 

$473.54 per month. In accordance with 

§ 100.2, the revised amount was 

effective upon its delivery by the 

Secretary to the Court. Such notice was 

delivered to the Court on November 13, 

2014. 

Dated: November 13, 2014. 

Mary K. Wakefield, 

Administrator. 

[FR Doc. 2014–27432 Filed 11–19–14; 8:45 am] 

BILLING CODE 4165–15–P 


rmajette on DSK2VPTVN1PROD with NOTICES